Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age21-45
SponsorNational University Health System, Singapore

About this trial

Gestational diabetes mellitus (GDM) is a transient hyperglycemic condition identified during pregnancy in women without a history of chronic diabetes. Evidence indicates that GDM can lead to various adverse health outcomes, including preterm birth, progression to pre-diabetes, and type 2 diabetes after delivery in mothers. Notably, GDM is becoming increasingly prevalent among Asian pregnant women due to rising rates of overweight and obesity, as well as genetic susceptibility. Despite growing recognition of GDM, its treatment efficiency and efficacy remain poor, primarily due to its heterogeneity, which is underpinned by various pathophysiological mechanisms.

Therefore, a better understanding of GDM heterogeneity can aid clinicians in providing more targeted treatment and follow-up strategies for GDM mothers. This study aims to define GDM phenotypes based on in vivo cardio-metabolic profiles and treatment response during pregnancy, utilizing advanced technologies such as continuous glucose profiling and untargeted metabolite profiling. In this proposed 3-year pregnancy cohort study, the investigators will recruit 800 overweight or obese Asian pregnant women in early pregnancy, without a history of diabetes, and follow them through to delivery. The goal of the study is to develop systematic antenatal and postnatal screening, treatment, and intervention guidelines for mothers with GDM.

Eligibility criteria

Qualifiers

Gestational age of ≤ 13 weeks 6 days

Overweight and obese subjects with BMI of 23kg/m² - 24.9kg/m² and ≥ 25.0kg/m², respectively

Aged 21-45 years with singleton pregnancy

Plan to be followed up during the whole pregnancy and deliver at NUH

Disqualifiers

Participants who are not Singapore citizens or Singapore Permanent Residents, not intending to eventually deliver in Singapore National University Hospital and to reside in Singapore for the next 2 years

Have serious skin conditions (eg. eczema) that precludes wearing the sensor for 14 days

With history of Type 1 diabetes or Type 2 diabetes

With chronic preexisting life-threatening conditions including pancreatic cancer, end-stage kidney dysfunction, and psychosis

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed